EDAP Edap Tms S.A. ADS

EDAP to Present at the Jefferies Global Healthcare Conference

EDAP to Present at the Jefferies Global Healthcare Conference

AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City. 

Presentation details:

Date:Thursday, June 5th
Time:4:20-4:50 PM ET
Webcast:

The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website .

About EDAP TMS SA

A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit .

Company Contact

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

50

Investor Contact

John Fraunces

LifeSci Advisors, LLC

(917) 355-2395



EN
27/05/2025

Underlying

EDAPEdap Tms S.A. ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Edap Tms S.A. ADS

 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP to Present at the Jefferies Global Healthcare Conference

EDAP to Present at the Jefferies Global Healthcare Conference AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City.  Presentation details: Date:Thursday, June 5th Time:4:20-4:50 PM ET Webcast: The live and archived webcast of the presentation can be accessed in the Investors section of th...

May 27, 2025 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP Reports First Quarter 2025 Financial Results

EDAP Reports First Quarter 2025 Financial Results           Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urology Association Annual Meeting (AUA 2025)Launched the New Focal One i Robotic HIFU System Performed World’s First Remote Transcontinental Focal One Robotic HIFU Procedure Successfully AUSTIN, Texas, May 15, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global lea...

May 15, 2025 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025 Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, ...

May 1, 2025 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP Announces Positive Results from the FARP Randomized Controlled Tr...

EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120th AUA Annual Meeting on Sunday, April 27, 2025. Study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up. AUSTIN, Texas, April 29, 2025 - EDAP TMS SA (Nasdaq: EDAP), ...

April 29, 2025 1 EN
 PRESS RELEASE
Free
EDAP Edap Tms S.A. A...

EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 12...

EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 120th American Urological Association (AUA) Annual Meeting Focal One i expands HIFUsion® patient-specific imaging compatibility to include PSMA PET, ExactVu™ Micro-Ultrasound, along with AI-driven and intelligent algorithms including Unfold AI™ and OnQ™ ProstateFocal One i extends HIFUsion capabilities to integrate Koelis® 3D biopsy maps and DynaCAD Urology datasetsFocal One i system will enable future capabilities including treatment streaming and recording, remote collaborative procedures and expanded clinical indications...

April 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch